Sunday 18 October 2026
Export IBO’s income statement to Excel — free account
Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022. In the quarter to June 2026, revenue fell 57.1%, EPS grew 99.5% and free cash flow grew 167.7%, each against the same quarter a year earlier.
2.68
0.48
−15.19%
Follow IBO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.52 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1,419.98 | 1,661.37 | 194.72 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
105.74 | (139.64) | 161.29 | (13.26) | |
P/B ratio |
3.55 | 4.40 | 1.03 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1,647.44 | 1,865.24 | 291.89 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(113.50) | (43.51) | (12.66) | (5.41) | |
EV/FCF |
(109.62) | (43.04) | (12.54) | (5.37) | |
Quick Ratio |
0.00 | 0.01 | 0.01 | 0.00 | |
Current Ratio |
0.16 | 0.22 | 0.35 | 0.04 | |
Net Debt/EBITDA |
0.02 | 0.01 | 0.00 | 0.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.67) | 0.20 | 0.02 | 0.42 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | — | (3.62) | |
Research and Development Expense of Revenue |
2,533.33% | 657.14% | 1,571.43% | 288.89% | |
Selling, General and Administrative Expense of Revenue |
5,566.67% | 23,157.14% | 1,714.29% | 1,461.11% | |
Intangible Assets out of Total Assets |
0.98 | 0.98 | 0.98 | 0.95 | |
Share Based Compensation of Revenue |
0.00% | 20,571.43% | 114.29% | (1,050.00%) | |
Graham Net Nets |
(0.05) | (0.03) | (0.09) | (3.22) | |
Graham Number |
20.28 | 0.00 | 0.00 | 101.67 | |
Earnings Yield |
191.37% | (48.47%) | (75.36%) | (590.83%) | |
Free Cash Flow Yield |
(1.06%) | (2.61%) | (11.95%) | (36.83%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.02 | |
Operating CF per Share |
0.06 | (0.05) | 0.04 | (0.64) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.06 | (0.05) | 0.04 | (0.64) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Shareholders Equity per Share |
1.64 | 1.72 | 6.23 | (9.17) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.64 | 1.72 | 6.23 | (9.17) | |
Free Cash Flow |
0.47 | (0.46) | 0.10 | (0.61) | |
Working Capital |
(1.72) | (1.31) | (0.75) | (22.88) | |
Net Current Asset Value |
(2.41) | (2.00) | (1.44) | (26.14) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.07 | 0.07 | |
Average Payables |
0.51 | 0.49 | 0.33 | 0.79 | |
Average Inventory |
0.27 | 0.28 | — | — | |
Average Assets |
17.90 | 18.57 | 18.85 | 32.45 | |
Average Common Equity |
3.29 | 10.73 | 11.37 | 12.69 |
Columns are period end dates · fundamentals updated 2 Oct 2026